Jul. 21 at 9:26 AM
$POET Which big pharma will take the opportunity or will we have a bidding war ?
Alzheimer AD:
Eisai Co., Ltd. &
Biogen Inc.:
$LLY
Axsome Therapeutics:
Novartis
AD CAGR approx. 9.2% – 19.5% (highest growth)
Schizophrenia:
$JNJ (Invega),
Otsuka & Lundbeck (Abilify/Rexulti),
$BMY (Cobenfy).
Parkinson's (PD):
AbbVie (Duodopa/Produodopa),
Amneal,
Supernus,
Teva.
ALS:
Mitsubishi Tanabe (Radicava),
Biogen (Qalsody for SOD1),
Sanofi (Riluzole).
Huntington's (HD):
Teva (Austedo),
Neurocrine Biosciences (Ingrezza).
FTD & MSA:
Teva
Sandoz
Viatris
The estimated global pharmaceutical revenue for 2026
Revenues approx.:
AD
$4.43 to 7.79 bn projected to rise sharply due to new antibodies including PMN310
Schizophrenia
$7.80 to 9.48 bn;
PD
$6.20 to 8.38 bn;
ALS
$0.95 to 1.03 bn;
HD
$720 to 868 mn;
FTD
$120 to 250 mn
MSA
$45 to 157 million.
https://www.promisneurosciences.com/news-media/press-releases/detail/269/promis-neurosciences-reports-first-human-evidence-of
